Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression
Document Type
Article
Publication Title
Gynecologic oncology
Abstract
BACKGROUND: Epithelial ovarian cancer (EOC) remains the most lethal gynecologic malignancy. The objective of this study was to compare the anti-tumor activity of HER2/neu-targeting monoclonal antibodies, trastuzumab (T), pertuzumab (P), combination of trastuzumab and pertuzumab (T+P) and trastuzumab-emtansine (T-DM1) in EOC with high HER2/neu expression. METHODS: Primary EOC cell lines were established and cell blocks were analyzed for HER2/neu expression. Cytostatic, apoptotic and antibody-dependent cell-mediated cytotoxicity (ADCC) activities of T, P, T+P and T-DM1 were evaluated in vitro. The in vivo antitumor activity was tested in xenograft models with 3+ HER2/neu expression. RESULTS: High (3+) HER2/neu expression was detected in 40% of the primary EOC cell lines. T, P, T+P, and T-DM1 were similarly effective in inducing strong ADCC against primary EOC cell lines expressing 3+ HER2/neu. The combination of T and P was more cytostatic when compared with that of T or P used alone (p<0.0001 and p<0.0001, respectively). T-DM1 induced significantly more apoptosis when compared with T+P (p<0.0001). Finally, T-DM1 was significantly more effective in tumor growth inhibition in vivo in EOC xenografts overexpressing HER2/neu when compared to T alone, P alone and T+P (p=0.04). CONCLUSION: In vitro and in vivo experiments with 3+ HER2/neu expressing EOC revealed limited anti-tumor activity of T or P. T-DM1 showed superior anti-tumor activity to T and P as single agents and as a combination. Our preclinical data support the design of clinical studies with T-DM1 for the treatment of chemotherapy-resistant EOC overexpressing HER2/neu.
First Page
145
Last Page
152
DOI
10.1016/j.ygyno.2017.07.009
Publication Date
10-1-2017
Recommended Citation
Menderes, Gulden; Bonazzoli, Elena; Bellone, Stefania; Altwerger, Gary; Black, Jonathan D.; Dugan, Katherine; Pettinella, Francesca; Masserdotti, Alice; Riccio, Francesco; Bianchi, Anna; Zammataro, Luca; de Haydu, Christopher; Buza, Natalia; Hui, Pei; Wong, Serena; Huang, Gloria S.; Litkouhi, Babak; Ratner, Elena; Silasi, Dan-Arin; Azodi, Masoud; Schwartz, Peter E.; and Santin, Alessandro D., "Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression" (2017). Obstetrics and Gynecology. 180.
https://scholar.bridgeporthospital.org/obgyn/180
Identifier
28705408 (pubmed); NIHMS893434 (mid); PMC5605415 (pmc); 10.1016/j.ygyno.2017.07.009 (doi); S0090-8258(17)31026-0 (pii)